{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+IV&page=3", "query": { "intervention": "Diphenhydramine IV", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 155, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+IV&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+IV&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T03:53:39.382Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06019728", "title": "A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Fabry's Disease" ], "interventions": [ { "name": "AGALSIDASE BETA (GZ419828)", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Loratadine", "type": "DRUG" }, { "name": "Cetirizine", "type": "DRUG" }, { "name": "Fexofenadine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "2 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2023-11-10", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-02T03:53:39.382Z", "location_count": 5, "location_summary": "Santa Monica, California • Atlanta, Georgia • Grand Rapids, Michigan + 2 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06019728" }, { "nct_id": "NCT02356159", "title": "Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Conditioning chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Hematopoietic stem cell transplant", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "IV Saline", "type": "OTHER" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "MUGA", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "BM aspirate", "type": "PROCEDURE" }, { "name": "BM biopsy", "type": "PROCEDURE" }, { "name": "Lumbar puncture", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-24", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-10-02T03:53:39.382Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02356159" }, { "nct_id": "NCT00641797", "title": "Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Benign Paroxysmal Positional Vertigo" ], "interventions": [ { "name": "Meclizine", "type": "DRUG" }, { "name": "Epley Maneuver", "type": "OTHER" }, { "name": "Lorazepam", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Lehigh Valley Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2006-11", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2018-04-03", "last_synced_at": "2026-10-02T03:53:39.382Z", "location_count": 1, "location_summary": "Allentown, Pennsylvania", "locations": [ { "city": "Allentown", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00641797" }, { "nct_id": "NCT00771875", "title": "Randomized Trial for Mixed Acute Rejection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Rejection" ], "interventions": [ { "name": "Rabbit Antithymocyte Globulin (RATG)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2008-09", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2016-01-27", "last_synced_at": "2026-10-02T03:53:39.382Z", "location_count": 2, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00771875" }, { "nct_id": "NCT04255420", "title": "SPG Blocks for Headaches", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Headache" ], "interventions": [ { "name": "SPG Block", "type": "PROCEDURE" }, { "name": "Standard IV Treatment", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Kendall Healthcare Group, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2020-02-21", "completion_date": "2021-06-01", "has_results": false, "last_update_posted_date": "2020-09-03", "last_synced_at": "2026-10-02T03:53:39.382Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04255420" }, { "nct_id": "NCT00887640", "title": "Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 11, "start_date": "2009-07", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-02-26", "last_synced_at": "2026-10-02T03:53:39.382Z", "location_count": 2, "location_summary": "Durham, North Carolina • Norfolk, Virginia", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887640" }, { "nct_id": "NCT02188719", "title": "Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Transplantation" ], "interventions": [ { "name": "Anti-Thymocyte Globulin - Rabbit", "type": "BIOLOGICAL" }, { "name": "darTreg Infusion", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Anti-Infective Prophylaxis", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Blood draws", "type": "PROCEDURE" }, { "name": "Liver biopsies", "type": "PROCEDURE" }, { "name": "Liver transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2014-12-17", "completion_date": "2019-06-18", "has_results": true, "last_update_posted_date": "2020-09-22", "last_synced_at": "2026-10-02T03:53:39.382Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188719" }, { "nct_id": "NCT05232825", "title": "A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis", "Primary Progressive Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab IV", "type": "DRUG" }, { "name": "Ocrelizumab SC", "type": "DRUG" }, { "name": "Methylprednisolone IV", "type": "DRUG" }, { "name": "Diphenhydramine IV", "type": "DRUG" }, { "name": "Dexamethasone given orally", "type": "DRUG" }, { "name": "Desloratadine given orally", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 236, "start_date": "2022-05-03", "completion_date": "2025-06-06", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-02T03:53:39.382Z", "location_count": 7, "location_summary": "Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more", "locations": [ { "city": "Maitland", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Owosso", "state": "Michigan" }, { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05232825" }, { "nct_id": "NCT07227597", "title": "A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer Extensive Stage" ], "interventions": [ { "name": "Gocatamig", "type": "DRUG" }, { "name": "I-DXd", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Rescue Medications", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2026-01-29", "completion_date": "2030-12-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-02T03:53:39.382Z", "location_count": 13, "location_summary": "Santa Rosa, California • Aurora, Colorado • Orlando, Florida + 10 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Edgewood", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227597" }, { "nct_id": "NCT04963296", "title": "A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Acetaminophen/Paracetamol", "type": "DRUG" }, { "name": "Diphenhydramine hydrochloride", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 303, "start_date": "2021-10-26", "completion_date": "2028-03-13", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-02T03:53:39.382Z", "location_count": 14, "location_summary": "Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04963296" } ] }